World News: 14:00 GMT Monday 16th April 2018. [EQS Group via SPi World News]
Bioprognos presents a revolutionary non-invasive test for the diagnosis of breast cancer
It is expected that the new test will save up to 90% of unnecessary breast biopsies that are usually done to confirm malignancy in suspicious findings in diagnostic imaging procedures
BIOPROGNOS (www.bioprognos.com [https://www.bioprognos.com/]) has signed an agreement with the ANDALUSIAN HEALTH SERVICE from Spain and the FUNDACIÓN ANDALUZA BETURIA PARA LA INVESTIGACIÓN EN SALUD (FABIS FOUNDATION) to exclusively market the results of a study in the form of a diagnostic test for breast cancer.
The advance presented by this group of researchers to the scientific community is the creation of a new probabilistic model that predicts the risk of breast cancer through a simple blood test. In this way, the sensitivity and specificity of all current analytical tests for the diagnosis of these patients will be improved, advancing even more in the early diagnosis. This will contribute to the improvement of its clinical evolution, resulting in a higher ratio of survival.
This research group has been working on the diagnosis of breast cancer disease for years, having identified an experimental algorithm based on a combination of different blood markers to diagnose it in early stages. These promising initial results were published in the scientific journal of Clinical Translational Oncology, of well-known reputation in the field of Oncology.
Besides, as part of the agreement, BIOPROGNOS will provide the necessary resources to continue the study, considerably expanding the number of patients through an international multicenter trial that will be developed in centers in Dominican Republic, France, Germany, Greece, India, Italy, Hungary, Poland, Romania, Russia and United Kingdom.
Moreover, Bioprognos presented the results of this study in the past XV National Conference of Gynecology and Obstetrics organized by HM HOSPITALES Y GABINETE VELÁZQUEZ, by Mª Dolores Ojeda MD, PhD (specialist in breast cancer with experience in comprehensive projects of the women health).
Finally, this study was awarded by the first prize in the XXV scientific meeting of the ANDALUSIAN SOCIETY OF CLINICAL ANALYSIS (SANAC), held from the 8th to 10th of March in Huelva, and selected from a total of 202 scientific projects accepted in the congress.
About FABIS Foundation
About HM Hospitals
About Gabinete Velázquez
Document title: Bioprognos presents a revolutionary non-invasive test for the diagnosis of breast cancer
Read More: http://www.dgap.de/dgap/News/?eqsNewsID=1688879
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.